Gennev Pricing Analysis and Total Cost: What You Actually Pay for Menopause Telehealth

What Gennev Is and How It Became Midi Health

Gennev launched in 2019 as one of the first telehealth platforms built specifically around menopause. The company offered virtual visits with menopause-trained OB-GYNs, health coaching, and a proprietary supplement line. In late 2023, Midi Health acquired Gennev, folding its patient base into a larger menopause and midlife care platform.

This matters for pricing. Post-acquisition, the Gennev brand now redirects to Midi Health's infrastructure in most markets, and the fee structure has shifted. Patients searching for "Gennev" today will typically land on Midi's booking flow, though some legacy Gennev branding persists on supplement products and older web pages. The North American Menopause Society (NAMS) has emphasized that menopause care remains significantly underserved, with only 20% of OB-GYN residency programs offering menopause training as of their 2021 workforce analysis [1]. Telehealth platforms like Gennev emerged partly to fill that gap. Whether the pricing reflects fair value depends on what you receive for the money.

Consultation Costs: Initial and Follow-Up Visits

The first visit is the most expensive line item. Cash-pay patients currently face initial consultation fees ranging from $150 to $250, though Midi Health's insurance integration has dropped the effective cost to $35 to $75 for patients with in-network coverage.

Follow-up visits, recommended every 3 to 6 months during the first year of hormone therapy, cost $65 to $175 for self-pay patients. A typical first year involves one initial visit and two to three follow-ups. That places consultation-only spending at $280 to $775 for cash-pay patients and $105 to $300 for insured patients before prescriptions enter the equation.

These figures align with broader telehealth pricing. A 2022 JAMA Network Open study (N=36.6 million visits) found that the median telehealth visit cost was $80 to $120 for specialty consultations, placing Gennev's cash-pay rates at the higher end of the market [2]. The premium reflects the niche specialization. General telehealth platforms may charge less per visit but rarely staff clinicians with NAMS certification or equivalent menopause-specific training.

Prescription Costs: What Gennev Clinicians Prescribe

Gennev clinicians prescribe FDA-approved hormone therapy and non-hormonal alternatives for menopause symptoms. The most common prescriptions include transdermal estradiol patches, oral or micronized progesterone (Prometrium), vaginal estrogen, and occasionally low-dose paroxetine (Brisdelle) for patients who cannot use hormones.

Prescription costs fall outside Gennev's direct fee structure. They depend entirely on pharmacy, insurance formulary, and drug choice. Some reference pricing:

• Estradiol patches (generic): $15 to $45 per month with insurance; $40 to $130 without [3]
• Prometrium (micronized progesterone): $10 to $30 with insurance; $30 to $90 cash pay
• Vaginal estradiol cream: $20 to $60 with insurance; $80 to $200+ without
• Brisdelle (paroxetine 7.5 mg): $30 to $50 with insurance; $300+ without (brand only)

The 2022 Endocrine Society clinical practice guideline on menopausal hormone therapy recommended transdermal estradiol as first-line for most symptomatic women, noting a lower venous thromboembolism risk compared to oral formulations [4]. Generic transdermal estradiol is among the least expensive HRT options. Patients prescribed branded products (Vivelle-Dot, Climara) will pay substantially more unless their plan covers them at generic-equivalent tiers.

A useful framework for estimating total prescription cost: multiply the monthly drug cost by 12, then add one annual lab panel ($100 to $300 cash; often covered by insurance). For a patient on generic estradiol patches plus generic progesterone with insurance, annual prescription spending is roughly $300 to $900. Without insurance, that figure can exceed $1,500 for multi-drug regimens.

The Supplement Line: Optional but Aggressively Marketed

Gennev built a proprietary supplement line targeting menopause symptoms. Products include formulations for sleep, hot flashes, bone density, and vaginal dryness. Pricing ranges from $30 to $55 per product per month.

This is where the total cost calculation gets important. A patient purchasing two supplements at $40 each adds $960 per year. Three products push the annual supplement spend past $1,400. These supplements are not covered by insurance, FSA, or HSA in most cases because they are classified as dietary supplements rather than medications.

The evidence base for menopause-targeted supplements varies. A 2023 Cochrane review of phytoestrogens for menopausal vasomotor symptoms (12 RCTs, N=1,692) found modest reductions in hot flash frequency but noted high heterogeneity across trials and preparations [5]. The NIH Office of Dietary Supplements has stated that evidence for black cohosh, a common ingredient in menopause supplements, remains inconclusive [6].

This does not mean the supplements have zero value. It means patients should weigh $40 to $55 monthly costs against evidence quality. Prescription HRT, by comparison, has strong evidence from the Women's Health Initiative follow-up data (N=27,347) showing clear symptom reduction and, for women starting within 10 years of menopause onset, favorable cardiovascular risk profiles [7].

Insurance Coverage: The Biggest Variable in Total Cost

The Midi Health acquisition changed Gennev's insurance picture significantly. Gennev originally operated as a cash-pay platform with limited insurance billing. Midi brought contracts with major insurers including Aetna, UnitedHealthcare, Cigna, and several Blue Cross Blue Shield plans.

For insured patients, the cost structure shifts dramatically. Visits become copay-based ($25 to $75 typical), and prescription coverage follows standard formulary rules. A 2024 analysis published in Menopause, the journal of NAMS, found that insurance coverage for FDA-approved HRT has improved over the past five years, with 89% of commercial plans now covering at least one form of systemic estrogen at Tier 1 or Tier 2 [8].

The gap remains for compounded hormones. If a Gennev/Midi clinician prescribes a compounded bioidentical formulation, insurance almost never covers it. Compounded HRT costs range from $30 to $150 per month through specialty pharmacies. The FDA has repeatedly noted that compounded hormones are not FDA-approved and do not undergo the same safety and efficacy testing as approved products [9]. Patients should clarify with their clinician whether prescribed formulations are FDA-approved generics or compounded preparations, as this single distinction can shift annual drug costs by $500 or more.

Gennev vs. Competitors: Price Comparison

The menopause telehealth market has expanded rapidly. Direct competitors include Evernow, Alloy Health, Elektra Health, and traditional OB-GYN telehealth through platforms like PlushCare or general primary care services.

Evernow charges approximately $175 for an initial assessment plus $49 per month for ongoing care, totaling roughly $763 for the first year (excluding prescriptions). Alloy Health bundles consultations with prescribed products, starting at $85 per month for an HRT regimen. Elektra Health emphasizes coaching and community alongside clinical visits, with membership plans starting around $75 per month.

Gennev/Midi's unbundled model can be cheaper for insured patients who only need clinical visits and standard prescriptions. A patient with good insurance might spend $350 to $700 total in the first year through Gennev, while Alloy's bundled model would cost $1,020 regardless of insurance. But for cash-pay patients adding supplements, Gennev's total can exceed $1,500, making it one of the more expensive options.

The 2023 NAMS position statement on hormone therapy emphasized that the decision to use HRT should be individualized based on symptom severity, risk profile, and patient preference, not on which telehealth brand markets most aggressively [10]. Price comparisons are useful only if the clinical quality is equivalent.

Is Gennev Legitimate? Evaluating Clinical Quality

Gennev is a licensed telehealth provider operating through board-certified clinicians. The platform is legitimate in the regulatory sense. Its clinicians hold active state medical licenses, prescriptions are routed through licensed pharmacies, and the platform complies with HIPAA and state telehealth regulations.

Clinical legitimacy is a separate question. The American College of Obstetricians and Gynecologists (ACOG) recommends that menopause management include a thorough history, assessment of cardiovascular and breast cancer risk, and shared decision-making about HRT [11]. Whether a 30-minute telehealth visit can replicate this depth of assessment is debatable, but research suggests telehealth-delivered menopause care produces comparable patient satisfaction and symptom outcomes. A 2022 observational study in Menopause (N=438) found no significant differences in treatment adherence or symptom improvement between telehealth and in-person menopause visits at 6 months [12].

The supplement sales component warrants more scrutiny. When the same entity prescribing your medication also sells you supplements, the potential for upselling exists. Patients should feel comfortable declining supplement recommendations without concern about care quality. A 2021 JAMA Internal Medicine analysis estimated that Americans spend $50 billion annually on dietary supplements, with limited regulatory oversight on efficacy claims [13].

Hidden Costs and Overlooked Expenses

Several costs do not appear on Gennev's pricing page but affect total spending.

Lab work: Baseline labs (lipid panel, metabolic panel, hormone levels) are standard before starting HRT. Without insurance, expect $100 to $400 depending on the panel. Some clinicians order repeat labs at 3 and 12 months. Quest Diagnostics and Labcorp offer self-pay pricing that is typically lower than hospital-based lab fees.

Pharmacy fees: Using a mail-order or specialty pharmacy may incur shipping fees of $5 to $15 per order. Patients filling prescriptions at retail pharmacies avoid this but may pay higher drug prices.

Subscription creep: Coaching sessions, supplement auto-renewals, and follow-up visit scheduling can accumulate. Track recurring charges. The FTC has increased enforcement against subscription services that make cancellation difficult, but patients bear the responsibility of monitoring auto-renewals [14].

Switching costs: If you start HRT through Gennev and later switch to an in-person provider, expect to pay for a new-patient visit ($200 to $500) and potentially repeat lab work. Transferring records is free under HIPAA, but clinical onboarding at a new practice is not.

Who Gets the Best Value from Gennev

The clearest value case: a patient with commercial insurance, moderate to severe vasomotor symptoms, and no interest in supplements. This patient pays copays for visits, gets FDA-approved generic HRT at formulary prices, and skips the supplement upsell. First-year cost: roughly $350 to $700.

The weakest value case: a cash-pay patient in a state where Midi does not hold insurance contracts, purchasing multiple supplements alongside prescriptions. First-year cost: $1,200 to $1,800+, which approaches or exceeds the cost of concierge in-person menopause care.

The CDC reports that approximately 1.3 million women reach menopause annually in the United States, with the median age of natural menopause remaining stable at 51 years [15]. For the subset experiencing symptoms severe enough to seek treatment, spending $350 to $700 per year for evidence-based HRT management is reasonable. Spending $1,500+ per year requires a clear-eyed assessment of whether each line item is clinically justified.

Check your insurance eligibility through Midi Health's verification tool before booking. If covered, request only FDA-approved generic formulations unless your clinician provides a specific clinical rationale for alternatives, and decline supplement purchases until you have discussed the evidence base with your prescriber.